Answers are grounded in this paper and cite their sources.
A multicenter randomized trial explores the effects of nivolumab on relapse in HPV-driven oropharynx cancers, suggesting potential benefits despite dosing challenges.
Induction nivolumab before CRT did not meet the predefined feasibility threshold because of reduced cisplatin dosing after toxicity in 10% of patients. The relapse incidence was numerically lower in the EA but this finding is exploratory and requires confirmation.
No takes yet. Share an insight, caveat, or question.
Mirghani et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: